Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | OSBP | P22059 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3693529 | 1.00 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1EPHA2APP | |
| SCHEMBL3690881 | 0.97 | POLA1 (0.46) | POLA1PLA2G2ACYP46A1EPHA2APP | |
| SCHEMBL11992542 | 0.96 | PLA2G2A (0.46) | POLA1PLA2G2ACYP46A1EPHA2APP | |
| SCHEMBL13116089 | 0.94 | POLA1 (0.49) | POLA1PLA2G2ACYP46A1EPHA2APP | |
| SCHEMBL14207243 | 0.93 | POLA1 (0.49) | POLA1PLA2G2ACYP46A1EPHA2APP | |
| SCHEMBL3691505 | 0.93 | POLA1 (0.49) | POLA1PLA2G2ACYP46A1EPHA2APP | |
| SCHEMBL3691508 | 0.93 | POLA1 (0.49) | POLA1PLA2G2ACYP46A1EPHA2APP | |
| SCHEMBL12011055 | 0.93 | POLA1 (0.49) | POLA1PLA2G2ACYP46A1EPHA2APP | |
| SCHEMBL19272838 | 0.90 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1EPHA2APP | |
| SCHEMBL13556705 | 0.90 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1EPHA2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081949-B1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | GE HEALTHCARE DHARMACON INC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8809514-B2 | Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference | GE HEALTHCARE DHARMACON, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8501706-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2064223-B1 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120322855-A1 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference | DHARMACON, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-8252755-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2081949-A2 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | Dharmacon, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2064223-A2 | DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | Dharmacon, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | DHARMACON, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2008036841-A2 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036825-A2 | DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | SNRPE, DCLRE1B, RNASE1 | POLA1 1228/4885PLA2G2A 2713/4885CYP46A1 3822/4885 |
| US-20120322855-A1 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference | SNRPE, AGO2, DCLRE1B | POLA1 716/4885PLA2G2A 2005/4885CYP46A1 4343/4885 |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | SRRT, SNRPE, SSBP1 | POLA1 361/4885PLA2G2A 1672/4885CYP46A1 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.